Table 2.

Univariate probabilities for occurrence of end stage liver disease (ESLD), hepatocellular carcinoma (HCC), and liver-related death (LRD) for 3, 5, 7 and 10 years following liver biopsy in the HepC-AK cohort according to the biopsy-confirmed fibrosis stage. Ninety-five percent confidence intervals shown in parentheses followed by number at risk.

Outcome	Time Period	Fibrosis Stage
		None/Mild (Ishak 0–1) (n = 150)	Moderate (Ishak 2) (n = 131)	Severe (Ishak 3–4) (n = 88)	Cirrhosis (Ishak 5–6) (n = 38)
ESLD	3-Year	0.7% (0.1, 4.6) (n = 121)	2.5% (0.8, 7.7) (n = 112)	8.7% (4.2, 17.5) (n = 65)	27.7% (15.8, 45.6) (n = 21)
	5-Year	1.7% (0.4, 6.8) (n = 96)	7.9% (4.0, 15.2) (n = 85)	16.4% (9.6, 27.2) (n = 52)	49.0% (33.0, 67.7) (n = 15)
	7-Year	5.1% (2.1, 12.1) (n = 80)	10.2% (5.6, 18.2) (n = 75)	23.9% (15.2, 36.4) (n = 40)	74.1% (56.4, 88.9) (n = 9)
	10-Year	8.4% (4.0, 17.3) (n = 48)	19.0% (11.6, 30.3) (n = 42)	39.3% (27.6, 53.9) (n = 25)
	# of Cases	12	20	31	26
HCC	3-Year	0.0% (0.0, 3.2) (n = 123)	0.0% (0.0, 3.4) (n = 116)	1.1% (0.2, 7.7) (n = 68)	3.3% (0.5, 21.4) (n = 29)
	5-Year	1.0% (0.1, 6.9) (n = 98)	1.0% (0.1, 6.6) (n = 89)	1.1% (0.2, 7.7) (n = 56)	13.4% (4.4, 36.7) (n = 18)
	7-Year	1.0% (0.1, 6.9) (n = 84)	2.3% (0.6, 9.1) (n = 72)	6.0% (1.9, 18.2) (n = 42)	35.0% (16.5, 64.4) (n = 12)
	10-Year	1.0% (0.1, 6.9) (n = 52)	4.6% (1.4, 4.8) (n = 45)	8.4% (3.1, 21.6) (n = 28)
	# of Cases	2	4	7	9
LRD	3-Year	0.0% (0.0, 3.2) (n = 124)	0.0% (0.0, 3.4) (n = 118)	1.4% (0.2, 9.6) (n = 70)	8.7% (2.9, 24.8) (n = 28)
	5-Year	0.0% (0.0, 3.2) (n = 95)	1.0% (0.2, 7.5) (n = 90)	4.7% (1.5, 13.9) (n = 56)	15.8% (6.8, 34.1) (n = 23)
	7-Year	1.2% (0.2, 8.1) (n = 84)	1.0% (0.2, 7.5) (n = 76)	6.9% (2.6, 17.6) (n = 46)	23.4% (11.8, 43.4) (n = 20)
	10-Year	1.2% (0.2, 8.1) (n = 54)	2.6% (0.6, 10.0) (n = 57)	12.1% (5.4, 25.6) (n = 31)
	# of Cases	1	4	13	19